Ibrutinib is the first in-class, orally administered, Bruton's tyrosine kinase (BTK) inhibitor that abrogates the critical signaling downstream of the B-cell receptor (BCR).
AbbVie has announced longer-term follow-up results from Phase III studies of Imbruvica (ibrutinib) in chronic lymphocytic leukemia and small lymphocytic...
Data from the investigational, randomized, multi-center, open-label Phase III RESONATE-2 (PCYC-1115) clinical trial show Imbruvica (ibrutinib), from Janssen/Pharmacyclics, was superior...
The past two decades have witnessed a paradigm shift in the management of patients with chronic lymphocytic leukemia (CLL), particularly with the introduction of targeted therapies to clinical practice.
A supplemental New Drug Application (sNDA) for Imbruvica (ibrutinib), from Janssen Biotech, has been submitted to the FDA for front-line...
The FDA has approved an expansion to the U.S. Prescribing Information (PI) for Imbruvica (ibrutinib), from Janssen, based on data...
AbbVie announced that the FDA has approved Imbruvica (ibrutinib) as a first-line treatment for patients with chronic lymphocytic leukaemia (CLL)....
TG Therapeutics announced positive topline results from its Phase III GENUINE clinical trial of TG-1101 (ublituximab) plus ibrutinib in patients...
AbbVie announced results from an analysis of data pooled from three Phase III studies evaluating Imbruvica (ibrutinib) use in patients...
BeiGene, Ltd. announced the FDA has approved a label update for Brukinsa (zanubrutinib) to include superior progression-free survival (PFS) results from the Phase III ALPINE trial comparing Brukinsa against Imbruvica (ibrutinib) in previously treated patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL).